Stimvia Announces Completion of Enrollment in Pilot Study for Parkinson’s Diseases and Essential Tremor
November 8th, 2023 – Stimvia, a company specializing in the use of neuromodulation for the treatment of chronic diseases, has successfully completed recruitment for a pilot study focused on the treatment of Parkinson’s disease (PD) and essential tremor (ET).
STIMVIA Unveils Innovative Solution to Transform CNS Disorder Treatments at TechCrunch Disrupt 2023
September 9th, 2023 – STIMVIA, a pioneer medical technology company, introduces an effective non-invasive neuromodulation treatment, URIS®, addressing deep brain structure dysfunctions linked to chronic conditions like overactive bladder.
STIMVIA Announces Promising Results from Clinical Study Regarding Overactive Bladder
June 13th, 2023 – STIMVIA a pioneer medical technology company focused on the development and commercialization of novel non-invasive neuromodulation for the treatment of lower urinary tract and bowel dysfunction, announces the publication of the safety and efficacy results of peroneal electrical Transcutaneous NeuroModulation (Peroneal eTNM®) delivered by URIS® neuromodulation system in patients with overactive bladder (OAB).
Stimvia receives the title of Visionary 2022 – December 2022
The CzechInno Association in Prague announced the winners of the twelfth year of the Visionaries project. The most beneficial innovative achievements of the Czech Republic and the Personalities of the Visionaries 2022 project were awarded.